Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||20 February 2014|
|PDF File Size:||3.26 Mb|
|ePub File Size:||12.50 Mb|
|Price:||Free* [*Free Regsitration Required]|
We recently showed that BEN hemodialysis patients required a higher dose of recombinant human erythropoietin for maintaining the target hemoglobin level than patients with other kidney diseases. The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients 40 BEN and 56 others who met the inclusion criteria.
Eritropoyetina Humana Recombinante –
Despite long clinical experience with ESAs, the mechanisms involved in their elimination have not been fully elucidated. It seems most likely that both native Epo and recombinant drugs are degraded following receptor-mediated uptake, mainly in the bone marrow.
The results were expressed as mean values erigropoyetina standard deviations. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Noncompartmental pharmacokinetic analysis using Kinetica software Thermo Scientific, ver. C reactive protein; Epo: This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Eritropoyetina Humana Recombinante
The present study was initiated from earlier data involving BEN and 94 non-BEN patients, which showed that significantly recombinxnte beta-Epo doses for reaching and maintaining target hemoglobin level were necessary in BEN than in non-BEN patients.
Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases non-BEN. Faculty of Pharmacy, University of Belgrade, Serbia. The Ethics Committee of the Clinical Center of Serbia evaluated and approved the study and the participants gave informed consent.
However, several authors reported no significant differences between anemia in BEN and other kidney diseases. The originating document has been archived. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator C.
Eritropoyetina Humana Recombinante Delta
Statistical analysis The results were expressed as mean values with standard deviations. On the other hand, residual renal function was maintained longer in BEN patients than in those with other kidney diseases 34 and our BEN patients were shorter on hemodialysis treatment than non-BEN patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each group used iron supplements.
Humanaa consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Eritropoyetina Humana Recombinante Delta –
Erythropoietin Epo concentration was determined in all samples on the same day by chemiluminescent immunoassay for erythropoietin on an Immulite analyzer Siemens Healthcare Diagnostics. Results of laboratory analyses in examined patients CRP: Comparison of two recombinant erythropoietin formulations in patients humaha anemia due to end-stage renal disease on hemodialysis: Although an impact of age on Epo elimination in our patients cannot be fully excluded, neither age nor other covariates that differed between the groups was found affect Epo elimination in the ANCOVA model.
The enigma of the metabolic fate of circulating erythropoietin Epo in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.
We comply with the HONcode standard for trustworthy health information – verify here. Therefore, not only the distribution by itself, but also the process of elimination and interaction directly with the Epo receptor on the red blood cell surface play an important role in increasing the values of Vd for Epo in comparison to its physiological distribution limited to extravascular space in the body.
By clicking Subscribe, I agree to the Drugs. This means it is still under development and may contain inaccuracies. In addition, iron status was assessed and supplementary iron given according to the same guidelines. Ciba Foundation Study Group No. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.
European best practice guidelines working group: A number of pharmacokinetic studies of ESA have been published, but comparison between them is difficult due to numerous methodological differences. Renal function, protein excretion and pathology of Balkan endemic nephropathy. Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients. In addition, recently described mechanisms independent of the Epo receptor elimination pathway, 29 may also contribute to slower Epo elimination in BEN patients.
Br J Clin Pharmacol ; Nephrol Dial Transplant ;19 Suppl 2: Colombia Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
However, the influence of ESA pharmacokinetics on hematopoietic response has not been sufficiently investigated. Eritropoyetina Humana Recombinante Eritropoyetina Humana Recombinante may be available in the countries listed below.
Serum levels of iron, ferritin, transferrin saturation, C-reactive protein CRPalbumin, urea, creatinine, calcium, phosphorus and parathyroid hormone PTH were determined in each patient at the time of study. J Clin Pharmacol Recent studies were largely devoted to the pharmacokinetics of new ESAs 10,12,14 and were usually carried out in healthy persons. Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.
Erythropoietin resistance and survival in non-dialysis patients with stage chronic kidney disease and heart disease.